These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36674755)

  • 1. Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells.
    Kalinovsky DV; Kholodenko IV; Kibardin AV; Doronin II; Svirshchevskaya EV; Ryazantsev DY; Konovalova MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.
    Kalinovsky DV; Kibardin AV; Kholodenko IV; Svirshchevskaya EV; Doronin II; Konovalova MV; Grechikhina MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment-Drug Conjugates Carrying Maytansinoids DM1 and DM4.
    Kalinovsky DV; Kholodenko IV; Svirshchevskaya EV; Kibardin AV; Ryazantsev DY; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
    Curr Issues Mol Biol; 2023 Oct; 45(10):8112-8125. PubMed ID: 37886955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies.
    V Kholodenko I; V Kalinovsky D; V Svirshchevskaya E; I Doronin I; V Konovalova M; V Kibardin A; V Shamanskaya T; S Larin S; M Deyev S; V Kholodenko R
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31653037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
    Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).
    Moutel S; Birkle S; Laurence V; Michon J; Fridman WH; Aubry J; Teillaud JL
    Hybridoma; 1997 Aug; 16(4):335-46. PubMed ID: 9309424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.
    Doronin II; Vishnyakova PA; Kholodenko IV; Ponomarev ED; Ryazantsev DY; Molotkovskaya IM; Kholodenko RV
    BMC Cancer; 2014 Apr; 14():295. PubMed ID: 24773917
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    McNerney KO; Karageorgos S; Ferry GM; Wolpaw AJ; Burudpakdee C; Khurana P; Toland CN; Vemu R; Vu A; Hogarty MD; Bassiri H
    Oncoimmunology; 2022; 11(1):2075204. PubMed ID: 35646475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.
    Nazha B; Inal C; Owonikoko TK
    Front Oncol; 2020; 10():1000. PubMed ID: 32733795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.
    Laopajon W; Takheaw N; Kotemul K; Pata S; Hongeng S; Kasinrerk W
    Explor Target Antitumor Ther; 2023; 4(6):1145-1156. PubMed ID: 38213540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.
    Zhao Q; Ahmed M; Guo HF; Cheung IY; Cheung NK
    J Biol Chem; 2015 May; 290(21):13017-27. PubMed ID: 25851904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
    Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
    Front Immunol; 2021; 12():690467. PubMed ID: 34367149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
    Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
    Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
    Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.